New drug combo shrinks tumors in most patients facing aggressive cancer type
The pancreatic cancer pill daraxonrasib shrank tumors in 60.7% of patients when paired with chemotherapy, and 8.2% saw tumors vanish on scans.
An early-phase clinical trial presented at a cancer conference revealed that combining the experimental pill daraxonrasib with standard chemotherapy significantly impacted advanced pancreatic cancer. Tumors shrank or stopped growing in over 90% of patients, with nearly double the median progression-free survival compared to chemotherapy alone. While side effects were manageable, researchers emphasize the need for larger trials to confirm these promising findings.
- An experimental pill, daraxonrasib, combined with gemcitabine and nab-paclitaxel chemotherapy, showed positive results in a phase ½ trial for advanced pancreatic cancer.
- In the trial of 61 patients, tumors shrank in 60.7% and stopped growing in 90.2% of cases.
- Patients experienced a median progression-free survival of 12.8 months, nearly double that of standard chemotherapy.
- Daraxonrasib targets the faulty RAS gene, which drives over 90% of pancreatic cancers.
- Larger Phase 3 trials are underway to confirm the efficacy and survival benefits of the new combination therapy.
Write a comment